The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Time-Limited Trials Near the End of Life
Abstract
CLINICIANS, PATIENTS, AND FAMILIES FREQUENTLY face scenarios in which they must make decisions near the end of life about whether to initiate major interventions in circumstances in which the outcome is uncertain. They do not want to prematurely forgo treatments that might help, but they also may not want to risk indefinite exposure to burdensome treatments. The possibility of a time-limited trial (TLT) of treatment may provide a way forward. A TLT is an agreement between clinicians and a patient/ family to use certain medical therapies over a defined period to see if the patient improves or deteriorates according to agreed-on clinical outcomes. If the patient improves, diseasedirected therapy continues. If the patient deteriorates, the therapies involved in the trial are withdrawn, and goals frequently shift more purely to palliation. If significant clinical uncertainty remains, another TLT might be renegotiated. A TLT begins with an assessment of the patient’s current clinical status, preferences, and prognosis with or without the treatment in question. In addition to disease-related factors, the patient’s cognitive and functional status is generally relevant. If the patient is unable to participate in decision making, surrogates should use “substituted judgment” to keep the patient’s voice alive. The benefits and burdens of initiating or forgoing the intervention, and whether knowledge about its efficacy for the patient can be ascertained within a specified time frame, should be carefully weighed. Clinical uncertainty impacts these decisions. For some patients, a 5% chance of surviving in any functional state will be enough to go forward, whereas for others any significant prospect of functional deterioration would preclude any trial of treatment. Some patients, as they get sicker, will accept treatments more aggressive than they thought they would when healthy. Physicians contribute to uncertainty as well, tending to err systematically in either optimistic and pessimistic directions when presenting poor prognostic information. Although patients and families generally want honesty with compassion when discussing prognosis, their desire to be told the truth may waver as prognosis gets worse. Many patients and families prefer their physicians to assist and often make challenging medical decisions on their behalf. Moreover, some patients are too ill to make these decisions themselves, so the burden of decision making falls on family members who may be hesitant about limiting any treatment. A strategy for discussing TLTs is outlined in the BOX. TLTs have 5 key sequential elements: 1. Define clinical problem and prognosis. All treating clinicians should agree about the patient’s medical status and treatment options. If some invasive life-sustaining therapies have already been started, are others likely to be needed in the future? How long will it take for a clear prognosis to emerge? Are some invasive treatments (eg, cardiopulmonary resuscitation) so unlikely to benefit the patient that some limits should be recommended from the outset? 2. Clarify the patient’s goals and priorities. Can the patient understand his or her clinical circumstances? If the paBox. Strategy for Discussing a Time-Limited Trial (TLT)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patterns of Functional Decline at the End of Life
Lunney, J. R. (2003) · JAMA · doi:10.1001/jama.289.18.2387 · Cited by 1,416
Quill, T. E., & Brody, H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-9-199611010-00010 · Cited by 723
Self-citationSystematic Review: The Effect on Surrogates of Making Treatment Decisions for Others
Wendler, D., & Rid, A. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-5-201103010-00008 · Cited by 691
Developing and Testing Changes in Delivery of Care
Berwick, D. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-8-199804150-00009 · Cited by 526
Cancer Patient Preferences for Communication of Prognosis in the Metastatic Setting
Hagerty, R. G., Butow, P. N., Ellis, P. A., Lobb, E. A., Pendlebury, S., Leighl, N., Goldstein, D., Lo, S. K., & Tattersall, M. H. N. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.095 · Cited by 503
Beyond Advance Directives: Importance of Communication Skills at the End of Life
Tulsky, J. A. (2005) · JAMA · doi:10.1001/jama.294.3.359 · Cited by 360
Discussing Treatment Preferences With Patients Who Want “Everything”
Quill, T. E., Arnold, R., & Back, A. L. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-5-200909010-00010 · Cited by 162
Self-citation
Cited by
Bagshaw, S. M., Stelfox, H. T., McDermid, R. C., Rolfson, D. B., Tsuyuki, R. T., Baig, N., Artiuch, B., Ibrahim, Q., Stollery, D. E., Rokosh, E., et al. (2014) · Canadian Medical Association Journal · doi:10.1503/cmaj.130639 · Cited by 555
Wiggins, J. E., Goyal, M., Sanden, S. K., Wharram, B. L., Shedden, K. A., Misek, D. E., Kuick, R. D., & Wiggins, R. C. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005050488 · Cited by 350
Khandelwal, N., Kross, E. K., Engelberg, R. A., Coe, N. B., Long, A. C., & Curtis, J. R. (2015) · Critical Care Medicine · doi:10.1097/ccm.0000000000000852 · Cited by 317
Holloway, R. G., Arnold, R. M., Creutzfeldt, C. J., Lewis, E. F., Lutz, B. J., McCann, R. M., Rabinstein, A. A., Saposnik, G., Sheth, K. N., Zahuranec, D. B., et al. (2014) · Stroke · doi:10.1161/str.0000000000000015 · Cited by 286
Self-citation
Metadata
- Authors
- Quill, T. E., & Holloway, R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-10-05
- Volume
- 306
- Issue
- 13
- Pages
- 1483
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2171685483
- Cited by
- 284
- References
- 8
- FWCI
- 13.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Time-Limited Trials Near the End of Life. https://app.cochat.ai/papers/10.1001/jama.2011.1413
- The paper
- Quill, T. E., & Holloway, R. (2011). Time-Limited Trials Near the End of Life. JAMA. https://doi.org/10.1001/jama.2011.1413
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.